At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 31 enrolled
Drug / intervention
Pirtobrutinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Single-Dose, Randomized, Partially Double-Blind, Placebo- and Positive-Controlled, 3-Way Crossover Study to Evaluate the Effect of LOXO-305 on QTc Interval in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Pirtobrutinib, Placebo, and 1 other intervention for Healthy. Completed, enrolled 31 participants across 2 sites.
Detailed Summary
The main purpose of this study is to assess the effect of Pirtobrutinib (LOXO-305) on the heart rate-corrected QT (QTc) interval and to conduct blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream and how the body handles and eliminates pirtobrutinib. The study will also evaluate the safety and tolerability of pirtobrutinib. The study will last up to 71 days, including screening.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsLoxo Oncology, Inc.
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartDec 2020
Primary CompletionMar 2021
First PostedJan 2024
TodayJul 2026
First PostedJan 22, 2024
Enrollment StartDec 15, 2020
Primary CompletionMar 31, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 2.4 years ago
Interventions
Pirtobrutinibdrug
Administered orally
Placebodrug
Administered orally
Moxifloxacindrug
Administered orally